NRG1 and neoplasm: While the European Society for Medical Oncology (ESMO) guidelines recommend the use of tumor NGS within clinical genomics programs and trials, particularly for accessing PARP and NRG1 inhibitors [41], this recommendation is contingent on access to targeted therapies and local cost-effectiveness assessments.